B-CELL LYMPHOMA

This early-phase study tests a new approach for people with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), modify them in the lab to recognize and attack cancer cells carrying the CD19 p…

This early-stage study tests an oral drug called LOXO-338 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. Participants must have already received standard treatments. The main goals are to find the safest dose and see if the drug helps control…

This early-phase study tests a new type of CAR T-cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) for people with B-cell lymphomas that have come back or not responded to standard treatments. About 15 adults will receive the therapy to see …

This study tests a combination of two drugs, palbociclib and ibrutinib, in adults with mantle cell lymphoma that has been treated before. The goal is to see if the combination can delay cancer growth or cause remission. About 39 participants will receive the drugs in 28-day cycle…

This early-phase study tests a "universal" CAR-T cell therapy (UWD-CD19) for people with B-cell cancers that haven't responded to standard treatments. About 30 participants will receive a single infusion of these engineered immune cells after a short chemotherapy prep. The main g…

This study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the tri…

This early-phase study tests a new drug, loncastuximab tesirine, added to a standard chemotherapy regimen (DA-EPOCH-R) for adults with aggressive B-cell lymphomas, including Burkitt lymphoma. The main goal is to find the safest dose by monitoring side effects. Only 11 participant…

This study was designed to see if the drug glofitamab can stop large B-cell lymphoma from returning in patients who are in complete remission but still have tiny traces of the disease (called minimal residual disease). The trial planned to enroll adults who completed standard che…

This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain blood cancers (B-cell ALL, lymphoma) will receive anakinra alongside their CAR-T treat…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This study tests a new type of CAR T-cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The main goals are to find the safest dose and…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …

This study looks at whether a blood test (liquid biopsy) can predict if lymphoma will come back within 1-2 years after first treatment, compared to the usual PET-CT scan. Researchers will follow 108 adults with B-cell or Hodgkin lymphoma after their first therapy. The goal is to …

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study monitors people who previously received AvenCell's CAR-T cell therapy for blood cancers or prostate cancer. The goal is to check for long-term side effects, including new cancers, nerve problems, or immune disorders. About 178 participants will be followed over time to…